Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Adobe | BUY $480 | ― | -1.70% | Reiterated | Analysts Offer Insights on Technology Companies: Adobe (NASDAQ: ADBE) and Semtech (NASDAQ: SMTC) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $65 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $8 | ― | 101.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $325→$395 | ― | 13.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38 | ― | 7.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20→$25 | ― | 8.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $8→$7.85 | ― | 3.70% | Downgraded | ||||
 | BridgeBio Pharma | BUY $72→$82 | ― | -3.40% | Reiterated | UBS Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $8 | ― | 13.40% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $26 | ― | 8.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2.5 | ― | 8.10% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $82 | ― | 1.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $460 | ― | 3.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2→$4 | ― | 4.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38→$40 | ― | 9.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 14.00% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $16 | ― | 14.00% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $200→$175 | ― | 24.50% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $118 | ― | 24.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $355→$410 | ― | 24.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120→$130 | ― | 24.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $7 | ― | 26.70% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5 | ― | 0.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $470→$420 | ― | 9.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $590 | ― | 14.90% | Reiterated | ||||
 | General Motors | BUY $55→$73 | ― | -2.00% | Upgraded | Positive Report for General Motors (GM) from Barclays | |||
 | RH | BUY $436→$385 | ― | -6.10% | Reiterated | Barclays Sticks to Its Buy Rating for RH (RH) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $255 | ― | 3.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $134→$141 | ― | 6.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $247 | ― | 17.50% | Reiterated | ||||
Alaska Air | BUY $56→$90 | ― | -5.90% | Upgraded | Wall Street Analysts Are Bullish on Top Industrial Goods Picks | ||||
| Aptiv | BUY $85→$105 | ― | -2.00% | Upgraded | Aptiv upgraded to Overweight from Equal Weight at Barclays | |||
 | Theravance Biopharma | BUY $28 | ― | -4.00% | Initiated | Theravance Biopharma initiated with a Buy at B. Riley | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $9 | ― | 4.40% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $11→$9 | ― | 4.40% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $4 | ― | 4.40% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $15→$10 | ― | 9.90% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $255→$220 | ― | 1.70% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $51 | ― | 8.80% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $335→$350 | ― | 7.50% | Reiterated | ||||
| Array Technologies | SELL $8→$7 | ― | -23.70% | Downgraded | Array Technologies downgraded to Underperform from Neutral at BofA | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $27→$28 | ― | 12.80% | Reiterated | ||||
| IDEAYA Biosciences | BUY $58 | ― | -0.70% | Reiterated | IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $84→$247 | ― | 8.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $251 | ― | 14.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $43→$44 | ― | 4.00% | Reiterated | ||||
 | Freshworks | BUY $25 | ― | -2.40% | Reiterated | Freshworks: Positioned for Growth with Strategic Financial Model and Expanding Market Opportunities | |||
 | Gilead Sciences | BUY $136→$143 | ― | -9.40% | Reiterated | Redburn Atlantic Sticks to Their Buy Rating for Gilead Sciences (GILD) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $415→$370 | ― | 9.10% | Upgraded | ||||
 | Tesla | BUY $374 | ― | -20.90% | Reiterated | Tesla (TSLA) Receives a Buy from TD Cowen |
Rows:
